: The UCLA APT CTU is a multidisciplinary, research group composed of a core administrative unit and four clinical research sites (CRS) in metropolitan Los Angeles and one CRS in Southern Brazil (Figure 1.1). We have over 20 years of leadership experience in the design, implementation, and conduct of clinical trials evaluating both therapeutic and prevention strategies in diverse populations across all age groups. Under the leadership of Judith Currier M.D., M.Sc. and an experienced multidisciplinary investigator team including Eric Daar, M.D., Margaret Keller, M.D., Karin Nielsen, M.D., Steve Shoptaw, Ph.D., Yvonne Bryson M.D., Ronald Mitsuyasu, M.D., Raphael Landovitz, M.D., Breno Santos, M.D., and Stephen Brown M.D., we will participate in the design and conduct of studies addressing the priority areas;Therapeutics for HIV/AIDS and HIV-Associated Infections in both Adults and Maternal/Pediatric Populations, Integrated Strategies to Prevent HIV Infection, and Vaccines to Prevent HIV Infection. The CTU has an administrative core and CRS at UCLA and additional CRSs at Harbor-UCLA Medical Center, UCLA Vine Street Clinic, AIDS Research Alliance (ARA) and in Porto Alegre, Brazil. The CTU provides a gateway for the contributions of a cadre of outstanding established and emerging investigators at UCLA to contribute to clinical trials in HIV/AIDS. The goal of the UCLA APT CTU is to enroll diverse populations (encompassing adult, maternal and pediatrics) of HIV-infected and at-risk individuals from urban Los Angeles and Southern Brazil into therapeutic and prevention trials.
The specific aims of our unit are to:
AIM 1 :To make significant contributions to the development, conduct and leadership of studies in adult, maternal and pediatric HIV therapeutics.
AIM 2 : To evaluate and optimize integrated strategies to prevent HIV infection in diverse populations AIM 3: To conduct Phase l-lll trials to evaluate novel vaccine strategies to prevent HIV in all age groups AIM 4: To mentor new investigators in cross-disciplinary HIV/AIDS research as it relates to improving treatment, care management and prevention in diverse populations, including substance users.
AIM 5 : To simulate and support community involvement in HIV/AIDS research by maintaining active CABs and by facilitating greater participation of women and racial/ethnic minorities in the clinical trils conducted at the UCLA APT CTU.

Public Health Relevance

Worldwide there are 33 million people estimated to be living with HIV infection. Progress in the development of effective antiretroviral therapy and both biomedical and behavioral interventions for the prevention of HIV/AIDS has been phenomenal in the past thirty years, yet many important challenges remain. The clinical trials unit proposed will conduct high impact studies to evaluate new approaches to treating HIV infection and related complications and to preventing new cases of HIV through biomedical and vaccine research.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-DR-A (S3))
Program Officer
Csedrik, Joanne E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of California Los Angeles
Los Angeles
United States
Zip Code
Nixon, Daniel E; Bosch, Ronald J; Chan, Ellen S et al. (2017) Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1-infected individuals with low-density lipoprotein cholesterol <130 mg/dL (AIDS Clinical Trials Group Study A52 J Clin Lipidol 11:61-69
Kelesidis, Theodoros; Tran, Thuy Tien T; Brown, Todd T et al. (2017) Changes in plasma levels of oxidized lipoproteins and lipoprotein subfractions with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy and associations with common carotid artery intima-media thickness: ACTG 5260s. Antivir Ther 22:113-126
Celum, Connie; Hong, Ting; Cent, Anne et al. (2017) Herpes Simplex Virus Type 2 Acquisition Among HIV-1-Infected Adults Treated With Tenofovir Disoproxyl Fumarate as Part of Combination Antiretroviral Therapy: Results From the ACTG A5175 PEARLS Study. J Infect Dis 215:907-910
Gulick, Roy M; Wilkin, Timothy J; Chen, Ying Q et al. (2017) Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial. Ann Intern Med 167:384-393
Bednasz, Cindy J; Venuto, Charles S; Ma, Qing et al. (2017) Efavirenz Therapeutic Range in HIV-1 Treatment-Naive Participants. Ther Drug Monit 39:596-603
Zhang, Yinfeng; Clarke, William; Marzinke, Mark A et al. (2017) Evaluation of a Multidrug Assay for Monitoring Adherence to a Regimen for HIV Preexposure Prophylaxis in a Clinical Study, HIV Prevention Trials Network 073. Antimicrob Agents Chemother 61:
Tenforde, Mark W; Yadav, Ashish; Dowdy, David W et al. (2017) Vitamin A and D Deficiencies Associated With Incident Tuberculosis in HIV-Infected Patients Initiating Antiretroviral Therapy in Multinational Case-Cohort Study. J Acquir Immune Defic Syndr 75:e71-e79
Currier, Judith S; Britto, Paula; Hoffman, Risa M et al. (2017) Randomized trial of stopping or continuing ART among postpartum women with pre-ART CD4 ? 400 cells/mm3. PLoS One 12:e0176009
Eshleman, Susan H; Hudelson, Sarah E; Redd, Andrew D et al. (2017) Treatment as Prevention: Characterization of Partner Infections in the HIV Prevention Trials Network 052 Trial. J Acquir Immune Defic Syndr 74:112-116
Kelesidis, Theodoros; Oda, Michael N; Borja, Mark S et al. (2017) Predictors of Impaired HDL Function in HIV-1 Infected Compared to Uninfected Individuals. J Acquir Immune Defic Syndr 75:354-363

Showing the most recent 10 out of 152 publications